drugset / Trial / NCT04945096
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators will conduct this prospective and randomized clinical trial, to evaluate the hematopoietic reconstitution, GVHD and relapse rate of patients after allo-HSCT with decitabine containing conditional regimen and NAC treatment.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2025-07-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetylcysteine | Other / unclassified | 1.2 g | Oral |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 2 mg/kg | — |
| Background | Busulfan | Small molecule | 3.2 mg/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 1.8 g | — |
| Background | Cyclosporin A | Unknown | 3 mg/kg | — |
| Background | Cytarabine | Small molecule | 2 g | — |
| Background | Mycophenolate Sodium | Unknown | 500 mg | Oral |
| Background | Semustine | Small molecule | 250 mg/m2 | — |